These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 23035063

  • 1. Severe relapses under fingolimod treatment prescribed after natalizumab.
    Centonze D, Rossi S, Rinaldi F, Gallo P.
    Neurology; 2012 Nov 06; 79(19):2004-5. PubMed ID: 23035063
    [No Abstract] [Full Text] [Related]

  • 2. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 06; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 3. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D, Gilden D.
    Neurology; 2012 Nov 06; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract] [Full Text] [Related]

  • 4. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
    Tur C, Montalban X.
    Mult Scler; 2014 Apr 06; 20(4):510-1. PubMed ID: 24468818
    [No Abstract] [Full Text] [Related]

  • 5. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 06; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 6. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 7. New disease-modifying therapies and new challenges for MS.
    Yadav V, Bourdette D.
    Curr Neurol Neurosci Rep; 2012 Oct 30; 12(5):489-91. PubMed ID: 22760478
    [Abstract] [Full Text] [Related]

  • 8. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B.
    Neurology; 2012 Mar 20; 78(12):928-30. PubMed ID: 22402856
    [No Abstract] [Full Text] [Related]

  • 9. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 20; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 10. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 11. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ.
    Mult Scler; 2014 Sep 17; 20(10):1381-90. PubMed ID: 24852928
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.
    Conway DS, Cohen JA.
    Mult Scler; 2014 Sep 17; 20(10):1280-1. PubMed ID: 25160120
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.
    J Med Econ; 2011 Sep 17; 14(5):617-27. PubMed ID: 21777161
    [Abstract] [Full Text] [Related]

  • 14. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 15. Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
    Wipfler P, Harrer A, Pilz G, Oppermann K, Afazel S, Haschke-Becher E, Sellner J, Trinka E, Kraus J.
    Acta Neurol Scand; 2014 Mar 17; 129(3):e12-5. PubMed ID: 24032536
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Cervera C.
    N Engl J Med; 2012 Aug 30; 367(9):871; author reply 872. PubMed ID: 22931328
    [No Abstract] [Full Text] [Related]

  • 17. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Mancini N, Clementi M, Burioni R.
    N Engl J Med; 2012 Aug 30; 367(9):871-2; author reply 872. PubMed ID: 22931329
    [No Abstract] [Full Text] [Related]

  • 18. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
    Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC.
    Nervenarzt; 2011 Oct 30; 82(10):1314-9. PubMed ID: 21656322
    [No Abstract] [Full Text] [Related]

  • 19. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr 30; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 20. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L.
    Ideggyogy Sz; 2014 Mar 30; 67(3-4):141. PubMed ID: 26118259
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.